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ABSTRACT
Aims/Introduction: The polyol pathway has long been involved in the pathogenesis of diabetic nephropathy. It remains still
unclear, however, how the polyol pathway is implicated in this process. We explored the effects of the enhanced polyol pathway on
renocortical tubular cells and glomeruli in experimentally-induced diabetes.
Materials and Methods: Transgenic mice (Tg) overexpressing human aldose reductase were made diabetic by streptozotocin and
followed for 8 weeks. Renocortical pathology, expressions of tonicity-responsive enhancer binding protein (TonEBP) and
carboxymethyllysine of advanced glycation end-products, were examined. Wild-type non-transgenic mice (Wt) were also made
diabetic and served as controls.
Results: Diabetic Tg showed augmented expression of TonEBP in renocortical tubular cells with vacuolated degenerative changes.
These structural changes were associated with pronounced deposition of carboxymethyllysine. There was a signiﬁcant increase in
kidney weight, glomerular size, and mesangial area in diabetic animals and there was a trend for more severe changes in these
measures in diabetic transgenic mice compared with those in control diabetic mice. Treatment with aldose reductase inhibitor
signiﬁcantly prevented polyol accumulation, mesangial expansion and expressions of TonEBP and carboxymethyllysine in diabetic Tg,
but its effects on the renal structure were equivocal in control diabetic Wt.
Conclusions: Our ﬁndings suggest that tubuloglomerular change might contribute to early diabetic nephropathy under the
inﬂuence of the enhanced polyol pathway. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00071.x, 2011)
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INTRODUCTION
The polyol pathway has long been considered as one of the
important initiating factors for functional and structural changes
in the diabetic kidney1–3. Mesangial cells accumulate polyols and
produce excessive matrix proteins under high glucose milieu4,5.
Inhibition of aldose reductase (AR), a key regulating enzyme of
the polyol pathway, has been shown to prevent the development
of proteinuria, or thickening of glomerular basement mem-
branes, in diabetic animal models6,7 and humans8,9. In humans,
AR gene polymorphism10 and high activities or protein levels of
AR in erythrocytes11,12 are reported to be associated with a high
incidence of diabetic nephropathy. However, despite the fact that
tubular cells are intimately related to glomerular function, little
attention has been paid to the relationship between tubular cell
changes and glomerular pathology in early diabetes.
Transgenic mice (Tg) overexpressing human AR (hAR) are
established to be useful for the evaluation of the effect of
the enhanced polyol pathway on the development of diabetic
complications1,13,14. This model expresses high levels of hAR
mRNA and protein in a variety of tissues and accumulates polyols
under galactosemia. Tg develop severe neuropathic changes under
both galactosemic and diabetic conditions15,16. More recently, this
model has been shown to cause augmented tissue damage in the
ischemic heart17,18. It is therefore intriguing to explore the effects
of overexpression of hAR on early kidney lesions in streptozotocin
(STZ)-induced hyperglycemic mice to know how the enhanced
polyol pathway inﬂuences renal tubular cells and glomeruli.
MATERIALS AND METHODS
Animals
Female Tg that express hAR were used in the present study.
Mice negative for the hAR gene were used as wild-type
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control animals (Wt). After birth, all animals were maintained
in plastic cages in rooms with a constant temperature of 25C
and 12-h light and dark cycle. All animals were given free
access to rodent standard chow (Oriental MF, Tokyo, Japan)
and water.
Production of Diabetic Mice and Laboratory Testing
Both Tg and Wt at the age of 8 weeks were made diabetic by
an intraperitoneal injection of streptozotocin (180 mg/kg; Sigma,
St. Louis, MO, USA, Lot. 55H1503). After a couple of days, they
became severely polyuric and polydipsic. Mice with glycemic
levels more than 19.25 mmol/L and with constant glycosuria
were identiﬁed as diabetic. For comparison, non-diabetic Tg and
non-diabetic Wt served as controls. After the onset of diabetes,
bodyweight and blood glucose levels from the tail blood were
measured serially. Blood glucose of the tail was measured by
reﬂectance meter using a paper strip (Antsense; Sankyo, Tokyo,
Japan).
Half of the animals in both the diabetic Tg and diabetic Wt
groups were given AR inhibitor (ARI; ONO 2235, 100 mg/kg
per day; kindly provided by ONO Pharmaceutical, Osaka,
Japan) daily by gavage after the onset of diabetes.
Tissue Carbohydrate Levels
After exsanguination, bilateral kidneys were extirpated and the
left kidney was processed for biochemical analysis. The right
kidney was weighed and processed for structural analysis. For
biochemical analysis, the kidney was separated into the cortex
and medulla and stored at )20C until measurement. Sorbitol
and fructose contents in tissues were measured by liquid chro-
matography with tandem mass spectrometry (LC/MS/MS)
methods described previously15,16. The concentrations were
expressed as nanomoles per milligrams per protein.
Kidney Morphometry
For the evaluation of glomerular size and mesangial areas at
light microscopic levels, kidney samples ﬁxed in 4% formalde-
hyde were dehydrated and embedded in parafﬁn. Then, 4-l
thick sections were stained with hematoxylin–eosin and periodic
acid-Schiff (PAS).
Only the surface cortical area on PAS stained sections were
used for the analysis of glomeruli. Total glomerular surface area
(TGSA), glomerular tuft surface area (GTSA) and mesangial
surface area (MSA) were measured on at least 50 randomly cho-
sen glomeruli, and mean values were obtained as a representa-
tive of an individual21. For the measurement of glomerular
basement membrane (GBM) thickness, small pieces of renal
cortex in each animal were ﬁxed in 2.5% glutaraldehyde, post-
ﬁxed in 1% osmium tetroxide and embedded in epon. Ultrathin
sections were stained with uranyl acetate and lead citrate. A total
of 20 electron micrographs were randomly taken on the periph-
eral capillaries in each glomerulus at a magniﬁcation of ·20,000.
The basement membrane thickness was then measured on at
least 200 points in each glomerulus by the orthogonal intercept
method22. All the morphometric analyses were carried out in a
double-blinded manner.
Western Blotting and Immunohistochemistry
To explore the expression of hAR and mouse AR (mAR) by
western blot analysis, renal cortical tissues from Wt and Tg with
or without 8-week diabetic duration were homogenized in Tris-
saline-acid (TSA)- phenylmethylsulfonylﬂuoride (PMSF) buffer
(pH 8.0) and centrifuged (13,000 g). SDS-PAGE was carried out
using the Xcell SureLock system (Invitrogen, San Diego, CA,
USA) in the reducing condition. The membrane was reacted
with antibodies to hAR19,20 or mAR23 and b-actin-speciﬁc anti-
body (Santa Cruz). A ﬁnal incubation was carried out with per-
oxidase-conjugated anti-rabbit or anti-goat IgG (Santa Cruz
Biotech, Santa Cruz, CA, USA) for 45 min at room temperature.
Immunodetection was carried out by enhanced chemilumines-
cence (Amersham-Pharmacia, Buckinghamshire, UK).
To identify the localization of AR and tonicity-responsive
enhancer binding protein (TonEBP) expressions in the renal
cortex and explore the topology of pathological changes, depa-
rafﬁnized sections of formalin-ﬁxed renal cortical tissues from
Wt and Tg with or without diabetes were immunostained with
antibodies to hAR, mAR, TonEBP, Na,K-ATPase a1 (Novus
Biologicals, Littleton, CO, USA) as a marker of distal convoluted
tubule (DCT), and aquaporin 2 (Almone Labs, Jerusalem, Israel)
as a marker of CCD24. Immunohistochemical staining based on
the streptavidin-biotin method was carried out on deparafﬁnized
sections using antibodies against hAR19, mAR23, TonEBP24 and
carboxymethyllysine (CML)25. Speciﬁcity was conﬁrmed by the
control staining carried out by omitting the ﬁrst antibodies or
sections were incubated with preabsorbed immune sera with
excessive antigens when available.
The staining reactions of TonEBP and CML were semiquanti-
tatively expressed as 0 (negative), 1 (faintly or only focally posi-
tive), 2 (clearly positive on <50% cells or strongly positive on
<20% cells), 3 (clearly positive on ‡50% cells or strongly positive
on ‡20% cells). The average scores were obtained from at least
three stained slides for each animal and the average value in
each group was compared among the group.
Statistical Analysis
Statistical comparison was made on the differences in mean val-
ues among multiple groups by using one-way analysis of vari-
ance with post hoc Scheffe’s test. Statistical signiﬁcance was
achieved if P-values were <0.05.
RESULTS
Clinical Data
Diabetes caused a signiﬁcant reduction in bodyweight in both
Tg and Wt, and there was no signiﬁcant difference in the
decrease between diabetic Tg and diabetic Wt (Table 1). Hyper-
glycemic levels were comparable between these two groups.
Kidney weight was signiﬁcantly greater in diabetic groups than
those in non-diabetic groups (P < 0.01 for both). The average
112 Journal of Diabetes Investigation Volume 2 Issue 2 April 2011 ª 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd
Hashimoto et al.
kidney weight value was the greatest in diabetic Tg, but there
was no signiﬁcant difference between diabetic Tg and diabetic
Wt. Treatment with ARI did not have an inﬂuence on the
changes in bodyweight or blood glucose levels. Reduction of kid-
ney weight approached near non-diabetic levels in diabetic Tg
when treated with ARI (P = 0.08), whereas ARI effects on
kidney weight in diabetic Wt were not clear.
Tissue Carbohydrate Levels
Tissue concentrations of glucose in the renal cortex were signiﬁ-
cantly increased in both diabetic Tg and diabetic Wt compared
with those in non-diabetic animals (Table 2). Sorbitol was
increased by 55% in Tg compared with non-diabetic Wt
(P < 0.02). Although glucose levels of diabetic Tg were similar
to those in diabetic Wt, sorbitol was increased 3.0-fold in dia-
betic Wt and 3.7-fold in diabetic Tg compared with the non-
diabetic groups (P < 0.01 for both). Fructose was also increased
3.2-fold in diabetic Wt and 4.5-fold in diabetic Tg compared
with their non-diabetic groups (both P < 0.01).
ARI treatment signiﬁcantly inhibited the increase in sorbitol
in diabetic Tg (P < 0.01), but not in diabetic Wt. In contrast,
there was no inﬂuence of ARI on fructose in diabetic Tg and
the level was rather increased in ARI-treated diabetic Wt com-
pared with untreated diabetic Wt (P < 0.01).
Kidney Structure and Morphometry of Glomeruli
In the renal cortex, both diabetic Tg and diabetic Wt showed
enlargement of glomeruli in addition to typical Ebstein–Armanni
lesions, showing watery vacuolation of tubular cells of the
cortical collecting duct (CCD). Glomerular capillary walls and
the mesangial area appeared to be expanded in both diabetic Tg
and diabetic Wt when compared with non-diabetic groups
(Figure 1). There was no apparent difference in the vacuolar
changes of tubular cells between diabetic Tg and diabetic
Wt. Treatment with ARI appeared to suppress the vacuolar
changes of tubular cells, swelling of glomeruli and expansion of
mesangial areas to a similar extent in both diabetic Tg and
diabetic Wt.
Morphometric analysis showed that TGSA, GTSA and MSA
were all greater in diabetic groups than in non-diabetic groups
(Table 3). Average values of these parameters were the greatest
in diabetic Tg, but the differences from diabetic Wt were not
statistically signiﬁcant. ARI treatment signiﬁcantly suppressed
the increase in MSA in diabetic Tg compared with the untreated
state (P < 0.05), but other measures were not affected. Effects of
ARI on the glomerular structure were also unremarkable in dia-
betic Wt.
At the ultrastructural levels, diabetic Wt showed dilated capil-
laries with a thin glomerular basement membrane (GBM), and
Table 1 | Bodyweight, blood glucose levels and kidney weight in experimental mice
Bodyweight (g) Blood glucose (mmol/L) Left kidney weight (mg)
Before After diabetes Before After diabetes After diabetes
Non-diabetic Wt n = 5 23.3 ± 2.6 28.8 ± 3.7 5.78 ± 0.88 6.38 ± 0.49 143 ± 17
Diabetic Wt n = 5 23.8 ± 2.1 20.0 ± 2.0† 6.42 ± 0.55 26.9 ± 0.9† 238 ± 23†
Diabetic Wt + ARI n = 5 22.6 ± 1.9 20.0 ± 1.8† 6.02 ± 0.41 27.2 ± 0.84† 220 ± 47†
Non-diabetic Tg n = 5 23.5 ± 3.6 29.3 ± 6.0 5.72 ± 0.83 6.32 ± 0.50 124 ± 15
Diabetic Tg n = 5 23.0 ± 1.9 19.7 ± 2.7‡ 6.11 ± 0.77 26.4 ± 1.62‡ 265 ± 54‡
Diabetic Tg + ARI n = 5 22.6 ± 2.8 19.8 ± 2.4‡ 5.88 ± 0.71 19.8 ± 2.42‡ 221 ± 33§
Values are mean ± SD. †P < 0.01 versus non-diabetic Wt, ‡P < 0.01 vs non-diabetic Tg, §P < 0.02 vs non-diabetic Tg.
ARI, aldose reductase inhibitor; Tg, transgenic expressing human aldose reductase; Wt, control wild-type mice.
Table 2 | Carbohydrate levels in the kidney cortex of experimental mice
Glucose (g)
(nmol/mg
wet weight)
Sorbitol
(nmol/mg
wet weight)
Fructose
(nmol/mg
wet weight)
Non-diabetic Wt n = 5 2.29 ± 0.14 0.036 ± 0.006 0.031 ± 0.001
Diabetic Wt n = 5 19.82 ± 3.95† 0.109 ± 0.021† 0.098 ± 0.031†
Diabetic Wt + ARI n = 5 20.11 ± 2.94† 0.108 ± 0.005† 0.160 ± 0.019†‡
Tg n = 5 2.29 ± 0.14 0.056 ± 0.011† 0.034 ± 0.002
Diabetic Tg n = 5 20.86 ± 1.86§ 0.207 ± 0.057§¶ 0.153 ± 0.022§¶
Diabetic Tg + ARI n = 5 20.90 ± 2.52§ 0.080 ± 0.015* 0.145 ± 0.005§
Values are mean ± SD. †P < 0.01 vs non-diabetic Wt, ‡P < 0.01 vs diabetic Wt, §P < 0.01 vs non-diabetic Tg, ¶P < 0.01 vs diabetic Wt, *P < 0.01 vs
diabetic Tg.
ARI, aldose reductase inhibitor; Tg, transgenic mice expressing human aldose reductase; Wt, control wild-type mice.
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dilated capillaries were also found in diabetic Tg, which often
showed an accumulation of basement membrane-like materials
near the mesangial area. ARI-treatment did not alter the appear-
ance of the ultrastructure in either diabetic Wt or diabetic Tg.
Quantitatively, although GBM in non-diabetic Tg was thickened
compared with that in Wt, the diabetic groups did not show
thickening of GBM at this stage and there was no difference
in the GBM thickness between diabetic Tg and diabetic Wt.
ARI-treatment did not inﬂuence the thickness of GBM.
Western Blot Analysis of AR
As expected, hAR expressions were constantly shown in both
the renal medulla and cortex in Tg (Figure 2), whereas hAR
was absent in Wt. In contrast, mAR was weakly expressed in
the cortical tissues in either Tg or WT in contrast to strong
reactions in the medulla. The diabetic condition enhanced the
hAR expression in Tg, but the effect on the expression of mAR
was uncertain.
Immunohistochemistry of AR, TonEBP and CML
There was a weakly positive reaction of constitutive mAR in the
cortical convoluted duct (CCD) and distal convoluted tubule
(DCT) in the cortex to a similar extent between Tg and
Wt (Figure 3). Diabetes for 8 weeks slightly enhanced the
immunoreactions in the tubular cells of CCD and DCT, but
the difference between diabetic Tg and diabetic Wt was not
apparent. A portion of mAR-positive cells were identiﬁed as
CCD, which were positive for aquaporin 2. TonEBP expressions
were also detected in cortical tubular cells and the diabetic con-
dition appeared to increase the expressions in both Tg and Wt
wt
wt + D Tg + D
wt + D + ARI Tg + D + ARI
Tg
Figure 1 | Microscopic features of the renal cortex in experimental mice stained with periodic acid-Schiff reaction. Both control wild-type (Wt) mice
(upper left) and transgenic mice expressing human aldose reductase (Tg; upper right) showed normal appearance. An 8-week diabetic condition
caused increased glomerular size and vacuolar degeneration of tubular cells both in Wt (left middle) and Tg (right middle). Treatment with aldose
reductase inhibitor (ARI) suppressed these changes in diabetic Wt (lower left) and diabetic Tg (lower right). Tg + D, diabetic transgenic mice;
Tg + D + ARI, ARI-treated diabetic Tg; Wt + D, diabetic control mice; Wt + D + ARI, diabetic control mice treated with ARI.
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(Figure 4). The localization of TonEBP was identiﬁed to be
DCT and CCD by staining of Na,K-ATPase a1, similar to the
site of mAR positive reactions. hAR was negative in the cortex
of control Wt and expressed in tubular cells only in Tg. The
expression of hAR was further enhanced in diabetic Tg in which
positive reactions were also found in the glomeruli as well as
tubular cells. Diabetic mice showed marked vacuolar degenera-
tive changes in CCD that were positive for TonEBP, particularly
in diabetic Tg. By treatment with ARI, the expression of
TonEBP was suppressed both in diabetic Tg and diabetic Wt.
Although there was no immunoreaction of CML in non-dia-
betic animals, expressions of CML were shown in tubular cells,
particularly of CCD and DCT, but not in the glomeruli in both
diabetic Wt and diabetic Tg (Figure 5). The expression of CML
was intensiﬁed in diabetic Tg compared with that in diabetic
Wt, and ARI treatment signiﬁcantly suppressed the expressions
in diabetic Tg. In a similar manner, although there were only
weak reactions of TonEBP in cortical tubular cells in non-
diabetic Wt and non-diabetic Tg (Figure 4), the reactions of
TonEBP were enhanced in diabetic Wt and diabetic Tg, the
latter of which showed more intensiﬁed reactions (Figure 6).
Treatment with ARI signiﬁcantly suppressed the expression of
TonEBP. The deposition of CML in tubular cells of CCD and
DCT underwent severe vacuolar degenerative changes and also
stained positive with hAR and TonEBP (Figure 7).
DISCUSSION
In the present study, 8 weeks of diabetic duration caused a sig-
niﬁcant accumulation of sorbitol and fructose in both Tg and
Wt, but to a greater extent in Tg than in Wt. Although there
was not as much AR in the renal cortex of mouse tissues com-
pared with the medulla, our results clearly showed the expres-
sion of mAR in tubular cells of CCD and DCT, and polyol
accumulation in the murine diabetic kidney. hAR expression
was widely distributed in Tg, including some proximal tubular
cells as well as glomerular cells. It is noteworthy that the diabetic
condition enhanced the expression of hAR and TonEBP in
tubular cells of DCT and CCD in both diabetic Wt and diabetic
Tg, but more prominently in the latter. Concurrently, CCD cells
showed increased expressions of CML associated with vacuolar
degenerative changes. The tubular changes of CCD and DCT
were accompanied by increased mesangial expansion in diabetic
Tg. Because CML represents advanced glycation end-products
(AGE) that mainly result from modiﬁcation of proteins by oxi-
dative stress25, increased ﬂux of the polyol pathway might exert
the release of free radicals, perhaps by downregulating glutathi-
one synthesis through the consumption of niconinamide ade-
nine diphosphate (NADPH), resulting in cellular injury16,17. The
fact that ARI suppressed such pathological changes in renal
tubular cells together with the reduction of the expanded
mesangial area in diabetic Tg might support the contention that
the enhanced polyol pathway might have a causal role in the
development of early diabetic nephropathy through alterations
of tubuloglomerular feedback systems26,27.
Immunohistochemical staining clearly disclosed the predomi-
nant site of constitutive mAR in CCD and DCT with the
expression of TonEBP. The localization of mAR was in keeping
with the site of osmoregulation for the transport of electrolytes
Cortex Medulla
Wt Wt + D Tg Tg Tg + DTg + D Wt Wt + D
hAR
mAR
Actin
Figure 2 | Expressions of human aldose reductase (hAR) and murine
aldose reductase (mAR) in experimental mice. hAR was expressed in
both the cortex and medulla in transgenic mice expressing hAR (Tg),
but not in control wild-type mice (Wt). In contrast, mAR was expressed
strongly in the medulla and less so in the cortex. Diabetic condition (D)
enhanced hAR expressions in both the cortex and medulla, whereas the
effects of diabetes (D) on the mAR expression were uncertain. Tg + D,
diabetic transgenic mice; Tg + D + ARI, aldose reductase inhibitor-
treated diabetic Tg; Wt + D, diabetic control mice; Wt + D + ARI,
diabetic control mice treated with aldose reductase inhibitor.
Table 3 | Morphometric data of the renal glomeruli in experimental mice
Total glomerular
surface area (mm2)
Glomerular tuft
surface area (mm2)
Mesangial
thickness (mm2)
Basement
membrane (nm)
Non-diabetic Wt n = 5 3406 ± 321 2625 ± 242 474 ± 43 218 ± 13
Diabetic Wt n = 5 4921 ± 704† 3594 ± 488† 737 ± 152† 218 ± 8
Diabetic Wt + ARI n = 5 4765 ± 374† 3480 ± 447† 607 ± 130 205 ± 18
Non-diabetic Tg n = 5 3307 ± 321 2477 ± 270 484 ± 46 249 ± 8‡
Diabetic Tg n = 5 5600 ± 836§ 3980 ± 515§ 803 ± 119§ 221 ± 25
Diabetic Tg + ARI n = 5 5043 ± 368§ 3523 ± 366§ 619 ± 83¶* 216 ± 12§
Values are mean ± SD. †P < 0.01 vs non-diabetic Wt, ‡P < 0.01 vs non-diabetic Wt and diabetic Tg + ARI, §P < 0.01 vs non-diabetic Tg, ¶P < 0.02 vs
non-diabetic Tg, *P < 0.05 vs diabetic Tg.
ARI, aldose reductase inhibitor; Tg, transgenic mice expressing human aldose reductase; Wt; control wild-type mice.
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and proteins27,28. In the present study, 8-week diabetes
enhanced the expression of AR and TonEBP in DCT and CCD,
which showed vacuolated cytoplasm, indicating that these cells
are a major target for the cellular injury by diabetes. Interest-
ingly, forced expression of hAR in the renal cortex further
enhanced the expression of TonEBP only at the site of CCD,
although the hAR expressions were more widely distributed.
The CML reactions were further enhanced in CCD and DCT in
diabetic Tg. It is therefore likely that vacuolar degenerative
changes might be related not simply to the hAR-induced ﬂux of
polyol pathway, but depend on the induction of TonEBP-medi-
ated osmotic imbalance or impaired electrolyte transport.
Upregulation of TonEBP in the cortex in response to diabetes
might be a result of increased local tonicity, which might in turn
augment expression of AR. In this setting, increased delivery of
tubular ﬂuid to the distal tubule might result in an increase in
interstitial tonicity as a result of elevated sodium reabsorption.
However, non-osmotic factors might also be involved in the
upregulation of TonEBP, because sorbitol accumulation is
shown to lower cellular potassium concentration and reduce
TonEBP expression in in vitro experiments29.
In previous studies, little attention has been paid to early tubu-
lar changes as the cause of development of diabetic nephropathy.
Most studies on the role of the polyol pathway concentrated on
only early glomerulopathy in diabetes, which has been ascribed to
intraglomerular metabolic abnormalities30,31. Excessive ﬂux from
glucose to sorbitol in the vessel wall, associated with an altered
redox state, was proposed to cause glomerular hyperﬁltration,
and structurally glomerular hypertrophy and mesangial expan-
sion32,33. In this setting, alterations of diacylglycerol and protein
mAR mAR
mAR mAR
DCT
CCD
Wt Tg
DCT
CCD
DCT
CCD
CCD
DCT
Tg + D
DCT
Wt + D
DCT
DCT
Tg + D
CCD
CCD
DCT
Wt + D
AQP2 AQP2
Figure 3 | Expression of murine aldose reductase (mAR) in experimental mice. Both control wild-type mice (Wt) and transgenic mice expressing
human aldose reductase (Tg) showed weak expression of mAR in tubular cells of distal convoluted tubules (DCT) and the cortical convoluted duct
(CCD). The expression of mAR was enhanced. In both diabetic Wt and diabetic Tg, the location of mAR was identiﬁed to be DCT and CCD by
positive reactions to aquaporin 2 (AQP2) in serial sections. Tg + D, diabetic transgenic mice; Tg + D + ARI, aldose reductase inhibitor-treated diabetic
Tg; Wt + D, diabetic control mice; Wt + D + ARI, diabetic control mice treated with aldose reductase inhibitor.
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kinase C activity in the glomerular vasculature were considered to
cause increased capillary permeability and structural changes34,35.
In addition, an increase in inducible nitric oxide synthase (NOS)
might also lead to altered glomerular hemodynamics in diabe-
tes36. In contrast to these hypotheses, the present study is the
ﬁrst to examine the relationship between renal tubular cells and
glomerular alterations by observing both glomerular structure
and renal tubular cells. In our previous study, we showed early
vacuolar alterations of macula densa and the reduction of con-
stitutive NOS activity in STZ diabetic rats from 6-week diabetes
duration37. With activation of polyol ﬂux, competitive consump-
tion of NADPH through conversion of glucose to sorbitol by
AR in tubular cells results in depletion of constitutive NOS,
altering the poor regulation of vascular tone at the site of the
juxtaglomerular apparatus37. Our current ﬁndings of early vacuo-
lar degeneration of CCD and DCT found in diabetic Tg might
therefore underlie the strong causal relationship between early
tubular changes and the enhanced polyol pathway at the site of
the juxtaglomerular area where the changes of CCD and DCT
contribute to glomerular alterations.
Our morphometric studies on renal glomeruli showed that the
diabetic condition led to increased kidney weight, and enlarge-
ment of glomerular size and the mesangial area. In the STZ dia-
betic model, early glomerular hypertrophy is characteristic.
Compared with diabetic Wt, diabetic Tg showed a trend of exag-
gerated glomerular pathology. ARI treatment signiﬁcantly sup-
pressed the increase in the mesangial area in diabetic Tg. It is not
clear, however, from our results whether tubular changes precede
TonEBP TonEBP
TonEBP TonEBP
*
*
*
*
*
*
* * *
*
*
#
#
#
* *
*
*
*
*
Wt Tg
Wt + D Tg + D
Wt + D Tg + D
#
*
*
*
*
*
*
*
*
* *
*
*
*
#
#
Na/K/ATPase α1 Na/K/ATPase α1
Figure 4 | Expression of tonicity-responsive enhancer binding protein (TonEBP) in experimental mice. Similar to the expression of murine aldose
reductase, TonEBP expression was found in distal convoluted tubules (DCT) in both control wild mice (Wt) and transgenic mice expressing human
aldose reductase (Tg). The expression of TonEBP appeared to be intensiﬁed in diabetic Wt (Wt + D) and diabetic Tg (Tg + D). Na,K-ATPase a1
immunostaining identiﬁed the TonEBP positive cells to be DCT and the cortical collecting duct (CCD). *DCT; #CCD. PT; proximal tubule.
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Wt Tg
Wt + D Tg + D
Wt + D + ARI Tg + D + ARI
AU
2.5
2.0
1.5
1.0
0.5
0.0
CML intensity
* *
*P < 0.05
Wt Wt + D Wt + D + ARI Tg Tg + D Tg + D + ARI
(a)
(b)
Figure 5 | Comparison of immunohistochemical expressions of carboxymethyllysine (CML), an advanced glycation end-product, in control and
diabetic mice. (a) In non-diabetic conditions, no positive reactions were detected in either control wild-type mice (Wt) or transgenic mice expressing
human aldose reductase (Tg). In diabetic conditions, positive reactions were detected in mainly distal convoluted tubules (DCT) as well as the
cortical collecting duct (CCD), and diabetic Tg (Tg + D) showed enhanced expressions compared with diabetic Wt (Wt + D). Treatment with aldose
reductase inhibitor (ARI) suppressed these reactions. (b) Semiquantitative evaluation conﬁrmed the augmented expression of CML in diabetic Tg
compared with diabetic Wt. Treatment with ARI suppressed the expression of CML. Tg + D + ARI, ARI-treated diabetic Tg; Wt + D + ARI; diabetic
control mice treated with ARI.
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glomerular pathology or vice versa, because we only examined a
single time-point. In the present study, we could only study a lim-
ited number of animals with 8-week diabetic duration. A longer
duration of more than 6 months with milder hyperglycemia to
examine the effects of the polyol pathway on the structural
glomerulopathy in diabetes in our model would be of interest.
Wt Tg
Wt + D Tg + D
Wt + D + ARI Tg + D + ARI
AU
4.0
3.0
2.0
1.0
0.0
TonEBP intensity
* *
*P < 0.05
Wt Wt + D Wt + D + ARI Tg Tg + D Tg + D + ARI
(a)
(b)
Figure 6 | Comparison of immunohistochemical expressions of tonicity-responsive enhancer binding protein (TonEBP) in control and diabetic mice.
(a) In non-diabetic conditions, only faint reactions were detected in either control wild-type mice (Wt) or transgenic mice expressing human aldose
reductase (Tg). In diabetic conditions, positive reactions were clearly detected in mainly distal convoluted tubules (DCT) as well as the cortical
collecting duct (CCD). Diabetic Tg (Tg + D) showed enhanced expressions of TonEBP compared with diabetic Wt (Wt + D). Treatment with aldose
reductase inhibitor (ARI) suppressed these reactions. (b) Semiquantitative evaluation conﬁrmed the augmented expression of carboxymethyllysine
(CML) in diabetic Tg compared with diabetic Wt. Treatment with ARI suppressed the expression of TonEBP. Tg + D + ARI, ARI-treated diabetic Tg;
Wt + D + ARI, diabetic control mice treated with ARI.
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In the present study, we could not ﬁnd signiﬁcant thickening
of the GBM in diabetic groups, although its thickness was
greater in Tg than Wt in the non-diabetic condition. Thickening
of the capillary basement membrane is characteristic in the ret-
ina or glomeruli in animal models when the polyol pathway is
activated under prolonged galactosemia (6–10 months)38 or dia-
betic condition39. Because early diabetes causes glomerular
hyperﬁltration with increased intraluminar pressure of glomeru-
lar capillaries33,40, GBM might be thinned as a result of capillary
dilatation with increased intraluminal pressure, and the thicken-
ing was not apparent at this early stage of diabetes.
The effects of ARI on tubular and glomerular changes were
not remarkable in diabetic Wt. This ﬁnding shows that
nephropathic changes in diabetic animals develop in part
under polyol-independent metabolic abnormalities. Non-enzy-
matic glycation30, excessive oxidative stress31 as well as altered
protein kinase C activities34,35 can be listed as other causative
factors. AGE are now established to comprise a variety of
glucose-derived or aldehyde-derived addicts of proteins41. CML,
a glucose-derived prototype of AGE, was deposited in renal
tubular cells in diabetic Tg and diabetic Wt, and its expression
was inhibited by ARI-treatment. Thus, non-glucose derived
AGE might also be implicated in the causation of diabetic
glomerulopathy, because pentosidine or pyrraline-type AGE
were shown to deposit in nodular lesions in the human diabetic
kidney42,43.
In conclusion, diabetic Tg were found to show marked tubu-
lar cell degeneration and CML deposition with polyol accumula-
tion, together with glomerular hypertrophy and mesangial
expansion. ARI treatment was partially effective to prevent
mesangial expansion only in diabetic Tg.
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